Eledon Pharmaceuticals (ELDN) Operating Expenses (2013 - 2026)

Eledon Pharmaceuticals has reported Operating Expenses for 14 years, with the latest figure at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 17.91% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (down 21.61% YoY), and the FY2025 full-year result was $7.5 million, up 14.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $21.2 million, up from -$54.3 million in the prior quarter.
• The five-year high for Operating Expenses was $58.7 million in Q4 2022, with the low at -$54.3 million in Q4 2025.
• Historically, Operating Expenses has averaged $9.8 million across 5 years, with a median of $11.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 525.34% — and 2024, when it plunged 480.52%.
• Eledon Pharmaceuticals' Operating Expenses stood at $58.7 million in 2022, then sank by 82.38% to $10.3 million in 2023, then sank by 480.52% to -$39.3 million in 2024, then sank by 38.02% to -$54.3 million in 2025, then jumped by 139.01% to $21.2 million in 2026.
• The last three Operating Expenses figures came in at $21.2 million (Q1 2026), -$54.3 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.